Lightair Ab · NGM:LAIR
Lightair Ab — Investor Presentation (May 2004)
35 slides from Lightair Ab's investor presentation, May 2004
Slide 1: Product presentation May 2004
® Product presentation May 2004
Slide 2: Light gives life
Light gives life Klicka här för att ändra format Light is energy Cells and organisms needs energy for survival and reproduction The Biolight®- method supplies essential energy to cells and organisms within the human body ®
Slide 3: Content
Klicka här för att ändra format Content 1. Biolight® – the method ® 2. Biolight – How it contributes to hospital care? ® 3. Biolight – areas of application ® 4. Biolight – products ® 5. Biolight – treatment instructions Appendix A. Clinical studies ®
Slide 4: 1. The method
Klicka här för att ändra format 1. The method ®
Slide 5: The Biolight method: pulsed monochromatic light
The Biolight method utilizes the biophysical effects Klicka här för att ändra format of pulsed monochromatic light (electromagnetic energy) in different combinations of •Wavelength •Amount of energy and strength •Pulsation •Area of application Monochromatic light 400-700 nm Blue Red UV -------------
Slide 6: Clinical effects
Clinical effects • Klicka här Faster healing för att ändra format • Pain relief • Reduced swelling Other • No side effects • Non-invasive • Documented effects – In-vitro studies… – …clinical phase III • CE-marked • Patent protected ® 1. Biolight® – the method
Slide 7: 2. How it contributes to hospital care
Klicka här för att ändra format 2. How it contributes to hospital care ®
Slide 8: Problems related to inflammatory conditions
Klicka här för att ändra format Problems related to inflammatory conditions? 1. Risk areas for complications • Open wounds, diabetic wounds,… • Infections • Loosening tooth conditions • Systemic diseases 2. Pain and discomfort for patients • Sick leave • Incapable to work 3. Demanding medical treatm
Slide 9: Infections, wounds, pain
Klicka här för att ändra 1. Infections, wounds, pain,… format • Risk for multi resistant bacterial spread? • Pain and discomfort? 89% of patients with pain (Ch Lindberg, KI) • Need for pharmaceutical treatment? • Surgical treatment? • Pain killers? • Risk for patient to become addicted? • Long time
Slide 10: Traditional treatment methods
Klicka här förtreatment 3. Traditional att ändra format methods • Pharmaceutical treatment • Pain killers – Drug dependence? – Drug dependence? – Side effects? – Side effects? – High costs? • Traditional wound treatment • Invasive treatment/Surgery – Isolates and protects wounds? – Extended sick lea
Slide 11: The ultimate treatment method
Klicka här för att ändra format The ultimate treatment method • Shortens healing and treatment time • Pain reliving • None addictive • No side effects • Non invasive • Easy to use and cost effective Will contribute to cost cuttings and improved quality! ® 2. Biolight® – how it contributes?
Slide 12: Biolight advantages and disadvantages
Klicka härBiolight för att ändra format ® Advantages Disadvantages • Active healing of wounds and other • Unknown method inflammatory conditions • Challenges well established • Reduces pain techniques • No side effects • Perceived as additional treatment time initially • Non invasive • All indicatio
Slide 13: Problems solved with Biolight
Klicka här för att ändra format Problems solved with Biolight® • Reduced risks for infections and complications! • Reduced pain during healing period! • Shortened time for rehabilitation! • Minimized risks for side effects! • Reduced costs for treatment! ® 2. Biolight® – how it contributes?
Slide 14: 3. Areas of application
Klicka här för att ändra format 3. Areas of application ®
Slide 15: Inflammatory conditions
Inflammatory conditions Klicka • Wounds här för att ändra format – Geriatric wounds – Diabetic wounds • Acute burns • Surgical wounds – After plastic surgery – Hip joints – Oral surgery • Inflammations caused by unsuitable working postures – Inflammatory conditions and injuries within sport • Period
Slide 16: 4. The product
Klicka här för att ändra format 4. The product ®
Slide 17: A portable and programmable device
• Klicka A portablehär för att device and programmable ändra format that provides emitting light and energy. • The energy is applied on the patient with a specifically developed diode (total instrument area 60 cm2) • Biolight® Care Device • Biolight® Biocards (treatment cards) • Biolight® vitamins-
Slide 18: Quality assurance and registration
Klicka här för att ändra format Quality Annex II MDD, ISO 13485:2003 Assurance MDD/93/42/EEC Registration FDA/510(k)/PCD ® 1. Biolight® – the product
Slide 19: Patents by country
Land Ansökta 1996 1997 1998 1999 2000 2001 2002 2003 Totalt Klicka här för att ändra format Sweden US 9 9 2 2 2 2 2 1 3 7 4 Canada 9 2 2 China 9 1 1 2 Germany 9 2 2 France 9 2 2 Switzerland 9 2 2 Austria 9 2 2 Belgium 9 2 2 Denmark 9 2 2 Spain 9 2 2 UK 9 2 2 Ireland 9 2 2 Italy 9 2 2 Netherlands 9 2
Slide 20: 5. Treatment instructions
Klicka här för att ändra format 5.Treatment instructions ®
Slide 21: Biolight Wound Care
Biolight® Wound Care Klicka här för att ändra format Biolight® illuminates the wound with pulsing infrared and visible red light. The treatment programs, loaded onto individual Biocards are designed for different types of wounds and specific areas for treatment (decubitus ulcers, bedsores, leg ulcer
Slide 22: Biolight Dental Care
Biolight® Dental Care Klicka här för att ändra format Biolight® illuminates the damaged area with pulsing infrared and visible red light. The treatment programs, loaded onto individual Biocards are designed for different types of dental wounds and specific areas for treatment (extraction, purificati
Slide 23: Biolight Physio Care
Biolight® Physio Care Klicka här för att ändra format Biolight® illuminates the damaged area with pulsing infrared and visible red light. The treatment programs loaded onto individual Biocards are designed for different types of wounds and specific areas for treatment (torn muscles, damaged ligament
Slide 24: Appendix
Klicka här för att ändra format Appendix ®
Slide 25: A. Clinical studies
Klicka här för att ändra format A. Clinical studies ®
Slide 26: Clinical studies overview: chronic ulcers
Titel Presenterad/publicerad Resultat Prövare Typ av studie META Klicka här för att ändra format Monochromatic Phototherapy in Patients with Chronic Ulcers, 16:e Nordiska Geriatriska kongressen i Odense, Danmark 2003. Posterpresentation vid Läkarstämman 2001, Riksstämma; GG15P/sid 195 29 % mindre så
Slide 27: Pressure ulcers Grade II analysis
Trycksår Klicka- Grad här IIför att ändra format Analysis (BL030 + BL034) n=163 (79 Biolight + 84 placebo) Difference in w eek 12 = 29,6%, p-value = 0,0394 100,0% 90,0% Biolight 80,0% Placebo Norm alized w ound area 70,0% 60,0% 50,0% 51% 40,0% 30,0% 20,0% 21% 10,0% 0,0% 10 11 12 e 1 2 3 4 5 6 7 8 9
Slide 28: Affymetrix study
Klicka här för att ändra format Affymetrix Biolight Placebo Incubation Incubation Fibroblasts Extraction Fibroblasts of mRNA Incubation onto micro arrays Analysis ® A. Biolight® - Clinical studies
Slide 29: Phase II study decubitus
Phase II-study Decubitus Klicka här för att ändra format Prospective, randomised, controlled study Biolight Control Patients 37 37 Reduction of area per day Grade II (62) +III (10) 5,3% 3,4% p<0,013 Grade II 5,9% 3,4% p<0,01 Improvements in healing ratio 54% (target was 40%) Healing to 90% - p<0,010
Slide 30: Microcirculation and tcPO2
Klicka härMicro Schubert; förcirculation att ändra and O format -tension 2 Transcutane partial O2-tension - tcPO2 Weekly registration of tcPO2 , every 5:th minute during 20 minutes, shows an increase of tcPO2 in group B (Biolight) compared with group A (control). Already after one week of treatment
Slide 31: Dental clinical studies overview
Titel Publicerad Resultat Prövare Typ av studie Gingivit Klicka här för att ändra format Presenterad vid Swedental 2001, Riksstämma; PKxx/sid xxx Signifikant snabbare läkning Lena Persson, Björn Klinge Fas III, Dubbelblind, Randomiserad, Placebo- kontrollerad Parodontit Utläkning kronisk parodontit
Slide 32: Gingivitis
Klicka här för att ändra format Gingivitis Gingival Index - > 1 n=47 patients (24 Placebo, 23 Biolight) Depuration 100 without Biolight 90 gives no improvement 80 GI change from baseline Biolight without 70 depuration 60 implies continues 50 Biolight, not clean improvement 40 Placebo, not clean Biol
Slide 33: Parodontitis
Klicka här för att ändra format Parodontitis Results after 3 months 80 60% 70 50% 60 PPD > 4 mm. Number of sites 50 40% Day 1 40 30% 3 months 30 20% % - improvem. 20 10 10% 0 0% 1 2 3 4 5 6 φ 7 Patient no. ® A. Biolight® - Clinical studies
Slide 34: Extraction of teeth
Klicka ofhär Extraction för att ändra format teeth •VAS, median, excl alveolites • 48 pat (24 Biolight & 24 Placebo) •Day 1 = surgery = day 0 •6.0 •5.0 •NSAID, median, excl alveolites • 48 pat (24 Biolight & 24 Placebo) •Day 1 = surgery = day 0 •Biolight •2.5 •4.0 •Placebo •Medianvärde •3.0 •2.0 •2.
Slide 35: Extraction of teeth: results one day after surgery
Klicka ofhär Extraction för att ändra format teeth Results one day after surgery Biolight Placebo 10 VAS 10 Median in Median in 8 study 8 study 7 7 6 6 5 5 4 4 3 3 Median in Median in 2 study 2 study 1 1 0 0 0 1 2 3 4 5 8 No of tablets 0 1 2 3 4 5 8 =1 =2 =3 =4 Σpatients = 24 in booth groups ® A. Bi